| Literature DB >> 32251805 |
Xun Li1, Luwen Wang1, Shaonan Yan1, Fan Yang1, Longkui Xiang1, Jiling Zhu1, Bo Shen2, Zuojiong Gong3.
Abstract
OBJECTIVES: This study aims to summarize the clinical characteristics of death cases with COVID-19 and to identify critically ill patients of COVID-19 early and reduce their mortality.Entities:
Keywords: COVID-19; Clinical characteristics; Death cases; Retrospective review
Mesh:
Year: 2020 PMID: 32251805 PMCID: PMC7128884 DOI: 10.1016/j.ijid.2020.03.053
Source DB: PubMed Journal: Int J Infect Dis ISSN: 1201-9712 Impact factor: 3.623
General clinical characteristics of 25 death cases.
| ID | Gender | Age | Course | Respirator | Underlying diseases |
|---|---|---|---|---|---|
| Patient1 | F | 55 | 17 | Y | Diabetes |
| Patient2 | M | 62 | 11 | Y | Diabetes, Hypertension |
| Patient3 | F | 81 | 17 | Y | Hypertension, Heart disease |
| Patient4 | F | 72 | 10 | Y | Diabetes, Hypertension, COPD, CRF, Heart disease |
| Patient5 | F | 83 | 7 | Y | Diabetes, Hypertension, CRF, Heart disease |
| Patient6 | M | 70 | 8 | Y | Hypertension |
| Patient7 | M | 73 | 9 | Y | Heart disease |
| Patient8 | F | 74 | 8 | Y | Heart disease |
| Patient9 | M | 82 | 7 | Y | Hypertension, Heart disease |
| Patient10 | M | 78 | 10 | Y | Hypertension, Hepatitis B |
| Patient11 | F | 78 | 9 | Y | Hypertension |
| Patient12 | F | 67 | 7 | Y | Diabetes |
| Patient13 | M | 94 | 14 | Y | Hypertension |
| Patient14 | F | 69 | 13 | Y | Heart disease |
| Patient15 | M | 90 | 9 | Y | Hypertension, Cerebral infarction |
| Patient16 | F | 75 | 7 | Y | Diabetes, Hypertension |
| Patient17 | F | 56 | 7 | Y | Diabetes, Hypertension, Alimentary tract hemorrhage, Nephrotic syndrome |
| Patient18 | F | 59 | 11 | Y | Diabetes, Hypertension |
| Patient19 | M | 56 | 17 | Y | Diabetes, Hypertension, Cerebral infarction, NAFLD |
| Patient20 | M | 74 | 8 | Y | Hypertension, Cerebral infarction |
| Patient21 | F | 55 | 10 | N | Pulmonary nodules, after lobectomy |
| Patient22 | F | 64 | 20 | N | lung cancer, chemotherapy |
| Patient23 | F | 74 | 19 | Y | lymphoma, chemotherapy, interstitial pneumonia |
| Patient24 | F | 56 | 5 | Y | Hypertension, acute pancreatitis, ureteral calculus, CRF |
| Patient25 | M | 100 | 4 | Y | Heart disease, COPD, Diabetes, CRF |
Analysis of laboratory test results of dead patients
| Laboratory findings | Test results (median, IQR) | Normal range | Total ( | Below the Lower ( | Above the Upper ( |
|---|---|---|---|---|---|
| Alanine transaminase (U/L) | 24 (16.5–46) | 9–50 | 25 | 1 (4) | 4 (16) |
| Aspartate aminotransferase (U/L) | 37 (29.5–57.5) | 15–40 | 25 | 0 (0) | 9 (36) |
| Albumin (g/L) | 32.81 (28.56–36.04) | 40–55 | 25 | 25 (100) | 0 (0) |
| Blood urea nitrogen (mmol/L) | 9.29 (6.07–16.4) | 3.6–9.5 | 23 | 2 (8.7) | 10 (43.5) |
| Creatinine (μmol/L) | 66 (49.5–161) | 57–111 | 24 | 9 (37.5) | 8 (33.3) |
| Hypersensitive troponin I (ng/mL) | 316 (57–5420) | 0–40 | 15 | 0 (0) | 11 (73.3) |
| Amino-terminal pro-brain natriuretic peptide (pg/mL) | 2450 (881–7992) | <75y: 0–125 | 17 | 0 (0) | 16 (94.1) |
| White blood cells (×109, cells/L) | 11.01 (7.51–15.39) | 3.5–9.5 | 25 | 3 (12) | 17 (68) |
| Neutrophils (×109, cells/L) | 10.41 (6.44–14.4) | 1.8–6.3 | 25 | 0 (0) | 18 (72) |
| Lymphocytes (×109, cells/L) | 0.52 (0.27–0.71) | 1.1–3.2 | 25 | 22 (88) | 0 (0) |
| Red blood cells (×1012, cells/L) | 3.82 (3.07–4.13) | 4.3–5.8 | 25 | 20 (80) | 0 (0) |
| Hemoglobin (g/L) | 121 (96–135.5) | 130–175 | 25 | 17 (68) | 0 (0) |
| Platelets (×109, cells/L) | 150 (123–212) | 125–350 | 25 | 7 (28) | 0 (0) |
| Procalcitonin (ng/mL) | 0.36 (0.13–1.91) | 0–0.1 | 21 | 0 (0) | 19 (90.5) |
| C-reactive protein (mg/L) | 91.1 (55.55–146.3) | 0–10 | 20 | 0 (0) | 19 (95) |
| Serum amyloid A (mg/L) | 300 (300–300) | 0–10 | 21 | 0 (0) | 21 (100) |
| Lactate (mmol/L) | 3.35 (1.96–5.1) | 0.5–1.5 | 16 | 0 (0) | 16 (100) |
| SARS-CoV-2 virus | Positive | Negative | 25 | 0 (0) | 25 (100) |
Below the Lower: Below the lower limit of normal range; Above the Upper: Above the upper limit of normal range.
Figure 1Chest CT scans of patient 3, patient 13 and patient 14.
A1: the early stage Chest CT scan of Patient 3; A2: the late stage Chest CT scan of Patient 3; B1: the early stage Chest CT scan of Patient 13; B2: the late stage Chest CT scan of Patient 13; C1: the early stage Chest CT scan of Patient 14; C2: the late stage Chest CT scan of Patient 14.
Specific biomarker that indicating poor prognosis
| Laboratory findings | The first test (median, IQR) | The last test (median, IQR) | Total ( | Increased ( | Decreased ( |
|---|---|---|---|---|---|
| Neutrophils (×109, cells/L) | 6.01 (3.09–8.90) | 10.36 (2–17.31) | 16 | 14 (87.5) | 2 (12.5) |
| Lymphocytes (×109, cells/L) | 0.62 (0.33–0.92) | 0.40 (0.13–1.1) | 16 | 12.5 (12.5) | 14 (87.5) |
| Procalcitonin (ng/mL) | 0.11 (0.07–0.24) | 1.12 (0.14–1.98) | 11 | 11 (100) | 0 (0) |
| C-reactive protein (mg/L) | 52.9 (19.55–79.8) | 96.2 (53.35–161.1) | 13 | 11 (84.6) | 2 (15.4) |
| Serum amyloid A (mg/L) | 300 (99.39–300) | 300 (300–300) | 12 | 5 (41.7) | 1 (8.3) |
| Hypersensitive troponin I (pg/mL) | 75 (37.5–258.5) | 293 (167.5–1023) | 9 | 7 (77.8) | 1 (11.11) |
| D-dimer (mg/L) | 1.18 (0.42–4.04) | 9.93 (2.65–54.8) | 12 | 9 (75) | 3 (25) |
| Lactic dehydrogenase (U/L) | 321 (250–372) | 510 (364–617.5) | 9 | 9 (100) | 0 (0) |
| Lactate (mmol/L) | 1.35 (0.68–1.5) | 2.75 (1.83–3.55) | 12 | 12 (100) | 0 (0) |
Increased, Decreased: Results of the last test vs. Results of the first test.